SLP - Simulations Plus Inc Stock Price, Fair Value and News

$20.37+0.84 (+4.30%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SLP Price Action

Last 7 days

17.8%

Last 30 days

20.3%

Last 90 days

44.3%

Trailing 12 Months

-35.0%

SLP RSI Chart

SLP Valuation

Market Cap

410.3M

Price/Earnings (Trailing)

-6.34

Price/Sales (Trailing)

5.18

EV/EBITDA

-6.21

Price/Free Cashflow

23.57

SLP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SLP Fundamentals

SLP Revenue

Revenue (TTM)

79.2M

Rev. Growth (Yr)

-6.45%

Rev. Growth (Qtr)

-14.26%

SLP Earnings

Earnings (TTM)

-64.7M

Earnings Growth (Yr)

-180.78%

Earnings Growth (Qtr)

98.99%

SLP Profitability

Operating Margin

79.70%

EBT Margin

-87.60%

Return on Equity

-51.86%

Return on Assets

-49.05%

Free Cashflow Yield

4.24%

SLP Investor Care

Dividend Yield

0.59%

Dividend/Share (TTM)

0.12

Shares Dilution (1Y)

0.39%

Diluted EPS (TTM)

-3.22

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	78.6M	80.4M	79.2M	0
2024	64.7M	67.0M	70.0M	74.4M
2023	54.4M	55.7M	59.6M	62.1M
2022	49.8M	52.0M	53.9M	53.5M
2021	45.7M	46.2M	46.5M	48.2M
2020	37.7M	40.1M	41.6M	42.9M
2019	31.2M	32.6M	34.0M	35.8M
2018	27.4M	29.2M	29.7M	30.1M
2017	21.1M	21.8M	24.1M	25.8M
2016	19.7M	19.7M	20.0M	20.6M
2015	14.4M	16.6M	18.3M	19.1M
2014	10.4M	11.0M	11.5M	12.9M
2013	9.8M	10.1M	10.1M	10.4M
2012	9.1M	9.2M	9.4M	9.5M
2011	0	0	8.7M	8.9M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems toxicology software; NAFLDsym; IPFsym; RENAsym; IPFsym; and MITOsym. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was incorporated in 1996 and is headquartered in Lancaster, California.

WEBSITE	simulations-plus.com
SECTOR	Healthcare
INDUSTRY	Health Information Services
EMPLOYEES	157

Simulations Plus Inc Frequently Asked Questions

What is the ticker symbol for Simulations Plus Inc? What does SLP stand for in stocks?

SLP is the stock ticker symbol of Simulations Plus Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Simulations Plus Inc (SLP)?

As of Wed Dec 03 2025, market cap of Simulations Plus Inc is 410.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLP stock?

You can check SLP's fair value in chart for subscribers.

Is Simulations Plus Inc a good stock to buy?

The fair value guage provides a quick view whether SLP is over valued or under valued. Whether Simulations Plus Inc is cheap or expensive depends on the assumptions which impact Simulations Plus Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLP.

What is Simulations Plus Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SLP's PE ratio (Price to Earnings) is -6.34 and Price to Sales (PS) ratio is 5.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Simulations Plus Inc's stock?

In the past 10 years, Simulations Plus Inc has provided 0.086 (multiply by 100 for percentage) rate of return.